The biggest documented Big Pharma scandals are not theories: they are guilty pleas signed before U.S. courts, fines paid to the Treasury, and settlements approved by judges. The most striking are the opioid affair (Purdue Pharma and the Sackler family), Merck's withdrawal of Vioxx in 2004, and the "off-label" marketing settlements of GlaxoSmithKline, Pfizer and Johnson & Johnson, each measured in billions of dollars. Before detailing them, an essential boundary: denouncing a proven commercial fraud never amounts to rejecting medicine or vaccines.
Definition. A "documented scandal" here means a matter recognised by a court decision: a guilty plea, a settlement agreement with the U.S. Department of Justice (DOJ), or a court ruling. We therefore exclude suspicions, rumours and untried accusations. The criterion is not outrage, but the piece of evidence.
This is the most emblematic scandal, because the product had genuine utility in pain relief — and it was its marketing that was found criminal. On 10 May 2007, the Purdue Frederick Company and three of its executives pleaded guilty, before the federal prosecutor for the Western District of Virginia, to having misled doctors, patients and regulators about the risk of abuse and dependence of OxyContin, a powerful opioid. The total settlement came to about $634.5 million (often rounded to $600 million).
On 21 October 2020, as part of a global resolution announced by the DOJ while the company was in bankruptcy, Purdue Pharma agreed to plead guilty again to three federal criminal counts (conspiracy to defraud the United States and impede the DEA, plus two counts of violating the Anti-Kickback Statute), in a resolution valued at up to $8 billion — including a $3.544 billion criminal fine and $2 billion in forfeiture, the heaviest penalties ever imposed on a pharmaceutical manufacturer. The Sackler family separately entered a $225 million civil settlement.
In the bankruptcy proceedings, the Sacklers proposed to pay billions (a plan ultimately set at $4.325 billion) in exchange for protection from any civil suit by the victims — a release imposed on third parties. On 27 June 2024, by 5 votes to 4, the U.S. Supreme Court struck down this mechanism (Harrington v. Purdue Pharma, opinion by Justice Gorsuch), holding that the Bankruptcy Code did not authorise such a nonconsensual release for the benefit of third parties who had not themselves filed for bankruptcy.
In the background, the Centers for Disease Control and Prevention (CDC) record roughly 800,000 opioid-related overdose deaths between 1999 and 2023, across several successive waves (prescription opioids, then heroin, then illicit fentanyl). The affair illustrates the dossier's central thesis: the same product can legitimately relieve a patient at the end of life and fuel a public-health catastrophe, depending on how it is sold and on whether its risks are stated — or concealed.
Not every scandal is pure marketing fraud. The Vioxx case poses a subtler question: that of a product's safety and the moment at which it is made public. Vioxx (rofecoxib), an anti-inflammatory of the COX-2 inhibitor class marketed by Merck, was voluntarily withdrawn from the world market on 30 September 2004, after the randomised APPROVe trial showed, beyond 18 months of treatment, an increased risk of confirmed cardiovascular events (heart attack, stroke) in treated patients compared with placebo.
In 2007, Merck agreed to a settlement of about $4.85 billion to resolve most U.S. civil patient litigation, with no admission of fault in that civil framework. In 2011, the company settled with the DOJ for $950 million: a guilty plea to a misdemeanour of introducing a misbranded drug into commerce, with a $321.6 million criminal fine, plus a $628.4 million civil component targeting off-label promotion and statements about cardiovascular safety. The scientific debate focused heavily on the delay between the appearance of the risk signal and its public handling — a question of information governance, which justifies no general distrust of anti-inflammatories.
The recurring core of the great convictions has a name: "off-label" promotion, that is, the active marketing by a manufacturer of a drug for uses the FDA has not approved. Three major cases resemble one another:
A decisive legal point: a doctor may legally prescribe off-label in the exercise of their judgment; it is the active promotion by the manufacturer of an unapproved use that is illegal. Many of these cases were, moreover, triggered by internal whistle-blowers, via the U.S. False Claims Act. These convictions target a way of selling, not the existence of the molecules: Risperdal, Bextra and Paxil had legitimate indications.
A pattern repeats: several distinct laboratories, several billion-dollar settlements in a few years, one and the same charge. The recurrence suggests that, for certain actors and during this period, the fine may have functioned as an operating cost rather than as a deterrent — if the revenue drawn from illegal promotion exceeds the fine incurred. This is a falsifiable hypothesis about incentives, not a claim that the drugs concerned were ineffective.
These settlements are almost always accompanied by a Corporate Integrity Agreement, imposing for five years obligations of compliance, audit and reporting. The very existence of this mechanism is an institutional admission: the fine alone does not correct behaviour. And one must stay honest about the amounts: they also reflect the size of the markets and the vigour of U.S. public action against Medicare and Medicaid fraud. The robust fact is not a spectacular total, but the dated and recognised existence of each offence.
This is the most important point of this article. Denouncing the documented commercial fraud of a laboratory validates no anti-vaccine theory and justifies no rejection of treatments. The convicted molecules had, for the most part, legitimate indications; what was found criminal was the lie about the risks, the withholding of data and the promotion of unapproved uses — not the principle of healing. An antibiotic saves lives even if the marketing surrounding it was condemned. These two truths coexist.
Saying "everything is rotten" is exactly the phrase that protects the fraudsters, by drowning their precise acts in a fog of general distrust. The rigorous stance is the opposite: demanding more transparency, more published data and more independence for the regulators means defending evidence-based medicine against what corrupts it, not condemning it.
What is the biggest pharmaceutical fraud settlement? GlaxoSmithKline's 2012 settlement, of $3 billion, was presented by the U.S. Department of Justice as the largest health-care fraud concluded at that date. Pfizer ($2.3 billion in 2009) and Johnson & Johnson ($2.2 billion in 2013) follow closely.
Do these scandals prove that the drugs are dangerous? No. They condemn commercial practices — off-label promotion, withholding of safety data, lying about the risks — not the therapeutic value of the molecules, which for the most part had legitimate indications. Recognising a marketing fraud validates no anti-vaccine or anti-science thesis.
What is off-label marketing? It is the active promotion, by the manufacturer, of a drug for a use that the health authority (the FDA in the United States) has not approved. Off-label prescription by a doctor is legal; promotion of an unapproved use by the manufacturer is not. This is the core of the great convictions.
To place these cases within the wider frame of the industry's convictions and fines, read the pillar article: Big Pharma, documented convictions and fines. And if you want the full file, piece by piece, with each dated amount and each court source in support, the investigation Big Pharma — The Documented Corruption takes up the whole of it.
GlaxoSmithKline's 2012 settlement, of $3 billion, was presented by the U.S. Department of Justice as the largest health-care fraud concluded at that date. Pfizer ($2.3 billion in 2009) and Johnson & Johnson ($2.2 billion in 2013) follow closely.
No. They condemn commercial practices — off-label promotion, withholding of safety data, lying about the risks — not the therapeutic value of the molecules, which for the most part had legitimate indications. Recognising a marketing fraud validates no anti-vaccine or anti-science thesis.
It is the active promotion, by the manufacturer, of a drug for a use that the health authority (the FDA in the United States) has not approved. Off-label prescription by a doctor is legal; promotion of an unapproved use by the manufacturer is not. This is the core of the great convictions.
Dossier : Big Pharma & souveraineté alimentaire
MINI15: Big Pharma — La Corruption Documentée
Accueil · Collection · Journal · Dossiers · Sources